CYTODYN
CytoDyn is a biotechnology company focused on the development of new therapies to combat infections with immune deficiency viruses. It has a unique and once-in-a-lifetime opportunity to possibly impact the IV/AIDS problem facing the world. CytoDyn will diligently pursue science and business opportunities, as presented, that may eventually benefit both shareholders and the world. CytoDyn developing subcutaneously delivered humanized cell-specific monoclonal antibodies (mAbs) as entry inhibitors ... for the treatment and prevention of Human Immunodeficiency Virus (HIV). The company intends to continue to develop PRO 140 as a therapeutic anti-viral agent in persons infected with HIV. They conducting a Phase 1b/2 clinical trial to evaluate its targeted therapy for the treatment of metastatic triple-negative breast cancer, the most aggressive type of breast cancer.
CYTODYN
Industry:
Biotechnology Pharmaceutical Therapeutics
Founded:
2002-01-01
Address:
Vancouver, Washington, United States
Country:
United States
Website Url:
http://www.cytodyn.com
Total Employee:
11+
Status:
Active
Contact:
(360) 980-8524
Email Addresses:
[email protected]
Total Funding:
89.48 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Universal Analytics Font Awesome
Similar Organizations
Aclaris Therapeutics
Aclaris Therapeutics is a specialty pharmaceutical company engaged in developing dermatologic therapies.
Adamas Pharmaceuticals
Adamas Pharmaceuticals develops controlled release combination therapeutics for infectious diseases and central nervous system disorders.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Axcella
Axcella is a biotechnology company that treats diseases using endogenous metabolic modulators.
Imvax
Imvax is a biotechnology company focused on the development of novel patient-specific vaccines and immunotherapy strategies.
Jounce Therapeutics
Jounce Therapeutics is developing cancer immune-therapies to harness the immune system to attack cancerous cells and tumors.
Ribon Therapeutics
Ribon Therapeutics is a biotechnology company focused on the development of therapeutics treatments targeting stress support pathways.
Current Employees Featured
Founder
Stock Details
Key Employee Changes
Official Site Inspections
http://www.cytodyn.com Semrush global rank: 2.4 M Semrush visits lastest month: 7.63 K
- Host name: ec2-174-129-30-187.compute-1.amazonaws.com
- IP address: 174.129.30.187
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149
More informations about "Cytodyn"
Leadership Team :: CytoDyn Inc. (CYDY)
CytoDyn is a publicly traded clinical stage biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. …See details»
Company Information :: CytoDyn Inc. (CYDY)
CytoDyn is a publicly traded clinical stage biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab, a novel humanized …See details»
Cytodyn - Crunchbase Company Profile & Funding
CytoDyn is a biotechnology company that focuses on the development of new therapies to combat infections with immune deficiency viruses.See details»
CytoDyn (CYDY) Company Profile & Description - Stock Analysis
3 days ago Company profile for CytoDyn Inc. (CYDY) with a description, list of executives, contact details and other key facts.See details»
Cytodyn - Org Chart, Teams, Culture & Jobs | The Org
View Cytodyn's up-to-date org chart, open roles, and culture details. Find executives, board members, teams, related companies, and more.See details»
CytoDyn Announces Data Suggesting Novel Mechanism of Action
5 hours ago CytoDyn is a clinical-stage biotechnology company focused on the development and commercialization of leronlimab, an investigational humanized IgG4 monoclonal antibody …See details»
Cytodyn Inc Company Profile - Cytodyn Inc Overview - GlobalData
Up-to-date Cytodyn Inc company overview including funding information, company profile, key statistics, peer comparison and more.See details»
Cytodyn Inc Locations - Headquarters & Offices - GlobalData
Cytodyn Inc headquarters address, phone number and website information and details on other Cytodyn Inc's locations and subsidiaries.See details»
CytoDyn Leadership Team To Attend ESMO Breast Cancer …
Apr 29, 2025 CytoDyn is a clinical-stage biotechnology company focused on the development and commercialization of leronlimab, an investigational humanized IgG4 monoclonal antibody …See details»
CytoDyn Company Profile | Management and Employees List
Find contact information for CytoDyn. Learn about their Research & Development, Business Services market share, competitors, and CytoDyn's email format.See details»
Investor Relations :: CytoDyn Inc. (CYDY)
Feb 24, 2025 Company Overview CytoDyn is a publicly traded clinical stage biotechnology company developing innovative treatments for multiple therapeutic indications based on …See details»
Cytodyn Company Profile - Office Locations, Competitors ... - Craft
Oct 29, 2024 Cytodyn has 1 employees at their 1 location and $300 k in annual revenue in FY 2022. See insights on Cytodyn including office locations, competitors, revenue, financials, …See details»
Cytodyn 2025 Company Profile: Stock Performance & Earnings
Information on stock, financials, earnings, subsidiaries, investors, and executives for Cytodyn. Use the PitchBook Platform to explore the full profile.See details»
Meet CytoDyn :: CytoDyn Inc. (CYDY)
CytoDyn is committed to enhancing the lives of patients through target specific medicine. Our team is focused on developing leronlimab, a monoclonal antibody CCR5 receptor antagonist, …See details»
CytoDyn Appoints Biotech Veteran Robert E. Hoffman as Chief
May 6, 2025 CytoDyn is a clinical-stage biotechnology company focused on the development and commercialization of leronlimab, an investigational humanized IgG4 monoclonal antibody …See details»
CytoDyn, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
5 days ago Explore CytoDyn, Inc. with its drug pipeline, therapeutic area, technology platform, 25 clinical trials, 147 news, and 16 literature, Disease Domain:Neoplasms ...See details»
Embattled CytoDyn Sets New Course Toward NASH, Tough Tumors
Mar 14, 2023 Before this doomed attempt, CytoDyn was developing the antibody for HIV. In October 2022, the company withdrew its Biologics License Application in this indication, citing …See details»
CytoDyn Announces New Data Suggesting Novel Mechanism Of
4 hours ago (RTTNews) - CytoDyn Inc. (CYDY.OB), a biotechnology company, Tuesday announced new data suggesting a novel mechanism of action of leronlimab for the treatment …See details»
CytoDyn Takes Steps towards a Brighter Future - Pharma's Almanac
Feb 6, 2023 CytoDyn will continue developing both the short- and long-acting versions of leronlimab. The goal is to bundle these two molecules together and find a strategic partner that …See details»
Pipeline :: CytoDyn Inc. (CYDY)
CytoDyn’s lead product, Leronlimab (PRO 140), is the world’s first self-injectable, subcutaneous injection for HIV.See details»